Diving for Data

Discussion around this is definitely part of the public discourse now but this is going to turn slowly like an ocean liner as incentives become more aligned.“The reimbursement of volume-based agreements is such a complex calculation to unwind, and people acknowledge that it is sensible but a hard thing to do. It takes a lot to move people off tried-and-true, low-risk ways of measuring the performance of a drug.Related Content: Rid Yourself Of Dirty DataTalking The Same LanguageNavigating the ChaosSeeking the Holy Grail of RWEThe Naked Truth About Outcomes-Based PricingPrimary Event: Value Summit USA 2018Pr écis: Finding the right data to underpin outcome-based contracts is not as easy as it looksPremium`: Freemium`: Channels: Access and EvidenceTags: value-based contracting

Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news